Biogen
About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.
Company Ownership: Public
Stock Symbol: BIIB
Stock Exchange: NASDAQ
Courage, resilience, hope. These are the qualities we seek to preserve. They are also the qualities that drive us to preserve them. Biogen – Where science meets humanity.
1750 articles with Biogen
-
Less than two months after joining the executive committee of the Voyager Therapeutics Board of Directors, Alfred W. Sandrock Jr. has been named CEO of the company.
-
Latest Findings On Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship To Clinical Outcomes And Dosing Regimens - Presented At AD/PD™ 2022 Annual Meeting
3/21/2022
Eisai Co., Ltd. and Biogen Inc. announced that the latest findings on lecanemab, an investigational anti-amyloid-beta protofibril antibody being developed for the treatment of early Alzheimer's disease, were presented at the Aβ Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases March 15-20 in Barcelona, Spain and virtually.
-
The data showed mixed end results, but the diagnostics involved in treating Alzheimer’s were the star of the conference.
-
It was a busy week for clinical trial announcements. Here's a look.
-
Genentech shared new data from its SUNFISH study evaluating the use of Evrysdi for SMA people ages 2 to 25 years diagnosed with Type 2 or Type 3 spinal muscular atrophy.
-
The U.S. Court of Appeals for the Federal Circuit denied Biogen a second look into the patent dispute filed against Mylan for Biogen's Multiple Sclerosis (MS) drug, Tecfidera.
-
Biogen reported new data from a long-term extension phase of the Phase III clinical studies of Aduhelm (aducanumab) for Alzheimer’s disease.
-
Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
3/16/2022
Biogen announced new data showing that after nearly two and a half years of treatment (128 weeks) with ADUHELM.
-
Biogen returned the rights to a dry age-related macular degeneration (dAMD) drug to Catalyst Biosciences. Biogen also ended the partnership regarding other dry AMD.
-
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
3/16/2022
Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer’s disease.
-
Tokyo-based Eisai Inc. and Biogen announced modifications to their existing collaboration on developing the drug Aduhelm (aducanumab).
-
Novartis released new data Monday from its Phase III SPR1NT trial that reinforces the benefits of Zolgensma.
-
Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
3/14/2022
Biogen Inc. (Nasdaq: BIIB) today announced new data and updates from its SPINRAZA® (nusinersen) and spinal muscular atrophy (SMA) research program aimed at improving clinical outcomes for people impacted by the disease, including the ASCEND, RESPOND and NURTURE studies.
-
In the latest results shared by the company, treatment with nusinersen for a median of 4.9 years helped participants maintain and make progressive gains in motor function.
-
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
3/14/2022
Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM® (aducanumab-avwa).
-
Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
3/11/2022
Biogen Inc. announced the company will present new Alzheimer’s disease research, as well as data for ADUHELM® injection 100 mg/mL for intravenous use, at the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases, taking place March 15-20 in Barcelona, Spain and virtually.
-
Health Canada Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab)
3/10/2022
Samsung Bioepis Co., Ltd. and Biogen Canada Inc. announced that Health Canada has approved BYOOVIZ™ – a biosimilar referencing LUCENTIS®i – for the treatment of neovascular age-related macular degeneration.
-
After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.
-
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.